anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a complex comprising a gold atom cluster and a nucleic acid structure, a method for preparing the same and a pharmaceutical composition for photothermal therapy comprising the same. The complex according to the present invention uses a nucleic acid structure formed by amplification of nucleic acid having high biodegradability and comprises a gold atom cluster having a diameter of 10 nm or less so that it may be discharged with ease. Thus, the complex according to the present invention has better bioapplicability as compared to the conventional complex comprising gold nanoparticles having a particle size of several hundreds of nanometers. The complex is controlled to have a diameter of 30 nm-100 m, and thus can infiltrate to cancer tissues with ease. In addition, as compared to a complex causing no agglomeration of gold ions upon irradiation of near infrared rays, the complex according to the present invention shows an increase in temperature of 30C or higher and reaches to the highest temperature up to 60C. Therefore, the complex according to the present invention can destroy cancer cells effectively and is useful for a pharmaceutical composition for photothermal therapy.
Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
PROBLEM TO BE SOLVED: To obtain the subject tablet having excellent disintegrating properties and solubility in an oral cavity, readily administrable and having a suitable strength by including an active ingredient, a lactose, a crystalline cellulose and light silicic acid anhydride in a specific proportion. SOLUTION: This tablet is obtained by including (B) 20-70 mass % of a lactose (e.g. α-hydrous lactose, α-anhydrous lactose or β-anhydrous lactose), (c) 20-50 mass % of a crystalline cellulose and (D) 0.1-10 mass % of light silicic acid anhydride in (A) at least one kind of an active ingredient. A low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, croscarmellose sodium, crospovidone, etc., may further be contained as a disintegrating agent in tablet. The above tablet is capable of exhibiting a disintegrating time within 30 sec in a disintegration test according to the Japanese Pharmacopeia and excellent disintegrating properties and solubility. The above tablet has 30-150 N tablet hardness without being damaged in production and distribution processes.
Hereditary hemorrhagic telangiectasia (HHT; Osler-Weber-Rendu disease) affects 1 in 5000 persons, making it the second most common inherited bleeding disorder worldwide. Telangiectatic bleeding, primarily causing recurrent epistaxis and chronic gastrointestinal bleeding, is the most common and most important manifestation of this multisystem vascular disorder. HHT-associated bleeding results in substantial psychosocial morbidity and iron deficiency anemia that may be severe. Although there remain no regulatory agency-approved therapies for HHT, multiple large studies, including randomized controlled trials, have demonstrated the safety and efficacy of antifibrinolytics for mild-to-moderate bleeding manifestations and systemic antiangiogenic drugs including pomalidomide and bevacizumab for moderate-to-severe bleeding. This has led to a recent paradigm shift away from repetitive temporizing procedural management toward effective systemic medical therapeutics to treat bleeding in HHT. In this article, 4 patient cases are used to illustrate the most common and most challenging presentations of HHT-associated bleeding that hematologists are likely to encounter in daily practice. Built on a framework of published data and supported by extensive clinical experience, guidance is given for modern evidence-based approaches to antifibrinolytic therapy, antiangiogenic therapy, and iron deficiency anemia management across the HHT disease severity spectrum.
PURPOSE:To obtain a bathing agent having body warming effects, skin smoothing effects, excellent fatigue recovering action and therapeutic action on the stiffness of the shoulders, being economically effective, containing an extract of stem and leaf of Matricaria chamonilla L. as an active ingredient. CONSTITUTION:Stems and/or leaves of Matricaria chamonilla L., a medicinal plant native to Europe are dried under the sunlight and extracted with a mixed solvent of water and an alcohol by using a closed container having a mixer blade. The extraction is carried out while stirring firstly, then while stirring under reduced pressure, further while stirring under reduced pressure and done under normal pressure. The prepared extract is used as it is or properly blended with vitamin, surfactant, germicide, antiseptic, perfume, dyestuff, etc., and prepared to give the objective substance. Usually about 10-200ml bathing agent is used in a household bathtub. A bathing agent component having more excellent qualities than the floral head is obtained from stems and leaves of Matricaria chamonilla L. which has been abandoned except floral head useful as crude drug.
Subjects with a chief complaint of musculoskeletal pain will be recruited from clinics in the Departments of Internal Medicine, Family Medicine, and Orthopedic Surgery. Subjects will be randomized into either the intervention or control group. The intervention group will receive education on sleep hygiene and instruction to use a foam roller to mobilize the thoracic spine and ribs just before the subject goes to sleep. The control group will receive education on sleep hygiene. Valid and reliable measures will be used to assess sleep quality (Pittsburgh Sleep Quality Index), pain (Numeric Pain Rating Scale), and function (SF-36 and ASES), as well as a sleep diary. Measures will be taken at baseline as well as two weeks after the subject's enrollment in the study.
PURPOSE OF REVIEW: Updated clinical practice guidelines for pulmonary fibrosis recommend early integrated palliative care using a primary palliative approach. Clinicians need to be aware of the various palliative interventions in order to implement guidelines' recommendations. This review provides an update on evidence-based palliative therapies.
RECENT FINDINGS: Literature review indicates early integration of palliative care in pulmonary fibrosis is feasible and meets patient needs. Key components of a primary palliative approach include comprehensive symptoms and needs screening, systematic symptom management using nonpharmacologic interventions, supplemental oxygen and opioids for dyspnea and cough. Patient-centered communication is essential for successful integration of palliative care. Early, iterative advance care planning in clinic to understand patient goals, values and preferences for current and future care, improves patient care and satisfaction. Prioritizing caregiver inclusion in clinics can address their needs. Collaborating with a multidisciplinary allied team facilitates integration of palliative care and supports patients throughout the disease course. Different models of palliative care delivery exist and can be adapted for local use. The use of artificial intelligence algorithms and tools may improve care and continuity.
SUMMARY: Clinicians must develop competency in palliative care. Organizational and policy support is essential to enable seamless integration of palliative care throughout the care continuum.
BACKGROUND: Augmentation of soft tissue repairs has been helpful in protecting surgically repaired tissues as they heal. FlexBand (Artelon, Marietta, Georgia) is a synthetic, degradable, polycaprolactone-based polyurethane urea (PUUR) matrix that has been investigated and used for soft tissue repair in a variety of settings. The purpose of this study was to evaluate the safety profile of a PUUR matrix in a large cohort of patients undergoing soft tissue repairs about the foot and ankle.
METHODS: A retrospective chart review of consecutive patients who underwent surgery using FlexBand to augment a soft tissue repair was performed to evaluate for major and minor complications related to the PUUR matrix. Results. A total of 105 patients with an average >6 months follow-up were included. The most common procedures were spring ligament repair, Achilles tendon repair, and Brostrom. There were 12 complications. Four major complications occurred with only 1 requiring PUUR matrix removal. Patients with wound complications had a higher body mass index (BMI) and rate of smoking.
CONCLUSION: Complication rates involving PUUR matrix in soft tissue foot and ankle reconstruction procedures are low and comparable with historical complication rates. The PUUR matrix is safe for use in a variety of soft tissue procedures about the foot and ankle.Level of Evidence: Level 4, Retrospective case-series.
Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion. If acute, severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.
In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
A method and compounds for promoting growth and activating the immune system in animals and humans are disclosed. The disclosed methods utilize compounds derived from one or more of lipopolysaccharide, lipid a, and portions, derivatives, and cellular components thereof of gram-negative bacteria. The compounds are combined with conventional feeds, such as corn-soybean feeds, for administration to animals, such as poultry. Human applications are also possible. The kinase-histologic analysis of tissues collected from sacrificed birds fed a dietary mixture of the compounds of the invention with conventional feed showed that biomass caused alterations in signaling in multiple growth-related pathways. These pathways include, but are not limited to, pathways associated with Vascular Endothelial Growth Factor (VEGF), mitogen activated protein kinase (MARK or MAP kinase), ak strain transformation (Akt), and neurotrophic tropomyosin-related kinase (NTRK). There is evidence that this change represents a conclusion of the regulation of the various pathways.
PURPOSE: Identifying pre/perioperative factors that predict corneal endothelial-cell loss (ECL) after phacoemulsification may reveal ways to reduce ECL. Our literature analysis showed that 37 studies have investigated one or several such factors but all have significant limitations. Therefore, the data of a large randomized controlled trial (PERCEPOLIS) were subjected to post-hoc multivariate analysis determining the ability of nine pre/perioperative variables to predict ECL.
METHODS: PERCEPOLIS was conducted in 2015-2016 to compare two phacoemulsification techniques (subluxation and divide-and-conquer) in terms of 3-month ECL. Non-inferiority between the techniques was found. In the present study, post-hoc univariate and multivariate analyses were conducted to determine associations between ECL and age, sex, cataract density, preoperative endothelial-cell density, phacoemulsification technique, effective phaco time (EPT), and 2-hour central-corneal thickness. The data are presented in the context of a narrative review of the literature.
RESULTS: Three-month data were available for 275 patients (94% of the randomized cohort; mean age, 74 years; 58% women). Mean LOCSIII cataract grade was 3.2. Mean EPT was 6 seconds. Mean ECL was 13%. Only an older age (beta = 0.2%, p = 0.049) and higher EPT (beta = 1.2%, p = 0.0002) predicted 3-month ECL. Cataract density was significant on univariate (p = 0.04) but not multivariate analysis. The other variables did not associate with ECL.
CONCLUSIONS: Older age may amplify ECL due to increased endothelial cell fragility. EPT may promote ECL via cataract density-dependent and -independent mechanisms that should be considered in future phacoemulsification research aiming to reduce ECL. Our literature analysis showed that the average ECL for relatively unselected consecutively-sampled cohorts is 12%.
PURPOSE:To reduce restrictiveness and invasiveness against the measurement of blood pressure, by a method wherein the blood pressures at intervals of a fixed time are measured with a time-zone, in which the blood pressure is at the lowest value, as the starting point, and on the basis of these measured values, a regression curve composed of curves each having different periods is made. CONSTITUTION:The diurnal fluctuation of blood pressure, which is information necessary for the diagnosis of hypertension and the determination of curative effect, is obtained by measuring blood pressure values and pulse rates per day, e.g. six points at intervals of four hours + or - a quater, with a time-zone, e.g. at 3a.m. + or -15min., in which the blood pressure is at the lowest value, as the starting point. That is, on the basis of the periodical regression analysis of the blood pressure values and the pulse rates at the six points obtained, the fit of two cosine curves, during 24 hours and 12 hours, is done and a blood pressure fluctuation level, i.e., a median, and a pattern, which is prescribed by a phase and an oscillation, are found. In this way, it is made unnecessary for a patient to always attach a blood pressure determination device to the body except that the patient is sleeping, and since only one or two points are measured even if the patient is usually sleeping, restrictiveness and invasiveness can be reduced.
Indocyanine green liposome and a large-scale preparation method and application thereof, belonging to the technical field of compound materials. The invention provides an indocyanine green liposome, which is obtained by synthesizing indocyanine green and embedding the indocyanine green into a lipid bilayer by utilizing the hydrophobic interaction of the indocyanine green and lipid micromolecules through a method of combining a thin film hydration-freeze thawing-high pressure homogenizer. Also provides a large-scale preparation method and application of the indocyanine green liposome. The method has high efficiency, good uniformity of the particle size of the liposome and consistent basic conditions for the liposome production, thereby improving the safety and effectiveness of the liposome in clinic. The production process of the invention has the advantages of less investment equipment, simple operation and low production cost, and is very suitable for industrial mass production. The indocyanine green injection solution is helpful for promoting the further clinical application of indocyanine green, and greatly reduces the clinical injection metering.
PURPOSE: This study proposed and evaluated a theoretical model for exploring the relationships between neurocognition, self-defeatist beliefs, experiential negative symptoms, and social functioning in individuals with chronic schizophrenia.
METHOD: The study recruited 229 individuals given a diagnosis of schizophrenia and schizoaffective disorders from outpatient clinics and the day ward of a mental health hospital. After informed consent was obtained, the participants underwent assessments using the backward digit span, the digit symbol, and measures of self-defeatist beliefs, experiential negative symptoms, and social functioning. A structural equation model was applied to assess the fitness of the hypothesized model, with indices such as the goodness-of-fit index, comparative fit index, root mean square error of approximation, and standardized root mean square residual being used for model evaluation.
RESULTS: The hypothesized model had an adequate fit. The study findings indicated that neurocognition might indirectly influence self-defeatist beliefs through its effect on experiential negative symptoms. Contrary to expectations, the study did not observe a direct influence of neurocognition, self-defeatist beliefs, or negative symptoms on social functioning. The revised model revealed the role of experiential negative symptoms in mediating the association between neurocognition and social functioning. However, self-defeatist beliefs did not significantly affect social functioning.
DISCUSSION: Before modifying negative thoughts, enhancement of self-awareness ability can help improve negative symptoms and thereby improve the performance of social functions. Future research should develop a hierarchical program of negative symptoms, from cognition rehabilitation to enhancement of self-awareness, and end with modifying maladaptive beliefs.
Osteoarthritis is characterized by enzymatic breakdown of the articular cartilage via the disruption of chondrocyte homeostasis, ultimately resulting in the destruction of the articular surface. Decades of research have highlighted the importance of inflammation in osteoarthritis progression, with inflammatory cytokines shifting resident chondrocytes into a pro-catabolic state. Inflammation can result in poor outcomes for cells implanted for cartilage regeneration. Therefore, a method to promote the growth of new cartilage and protect the implanted cells from the pro-inflammatory cytokines found in the joint space is required. In this study, we fabricate two gel types: polymer network hydrogels composed of chondroitin sulfate and hyaluronic acid, glycosaminoglycans (GAGs) known for their anti-inflammatory and prochondrogenic activity, and interpenetrating networks of GAGs and collagen I. Compared to a collagen-only hydrogel, which does not provide an anti-inflammatory stimulus, chondrocytes in GAG hydrogels result in reduced production of pro-inflammatory cytokines and enzymes as well as preservation of collagen II and aggrecan expression. Overall, GAG-based hydrogels have the potential to promote cartilage regeneration under pro-inflammatory conditions. Further, the data have implications for the use of GAGs to generally support tissue engineering in pro-inflammatory environments.
PURPOSE:To obtain diretly the titled microcapsule having a film containing a surface active agent, showing improved water dispersibility, capable of releasing even an unstable active substance sustainedly, by dissolving a specific polymer, a liquid active substance, and a surface active substance in an organic solvent, subjecting the solution to spray drying. CONSTITUTION:A polymer, a liquid active substance, and surface active agent are dissolved in an organic solvent, the solution is sprayed from a nozzle into very small liquid droplets, the solvent is dried, and the active substance is sealed in the film of the polymer, to give the titled microcapsule containing the surface active agent in the film. The polymer used dissolves the liquid active substance in a limited solubility, especially in 0.01-2wt%. The organic solvent used has higher volatility (e.g., methylene chloride, etc.) than the active substance. The microcapsule is formed in a gas, water is not admixed, and the liquid active subtance has good stability. The microcapsule has improved dispersibility, and is useful as a spray agent or wettable powder.
OBJECTIVES: Previous studies have demonstrated that obesity may impact the efficacy of anti-PD1 therapy, but the underlying mechanism remains unclear. In this study, our objective was to determine the prognostic value of obesity in patients with oral tongue squamous cell carcinoma (OTSCC) treated with pembrolizumab and establish a subtype based on fatty acid metabolism-related genes (FAMRGs) for immunotherapy.
MATERIALS AND METHODS: We enrolled a total of 56 patients with OTSCC who underwent neoadjuvant anti-PD1 therapy. Univariate and multivariate Cox regression analyses, Kaplan-Meier survival analysis, and immunohistochemistry staining were performed. Additionally, we acquired the gene expression profiles of pan-cancer samples and conducted GSEA and KEGG pathway analysis. Moreover, data from TCGA, MSigDB, UALCAN, GEPIA and TIMER were utilized to construct the FAMRGs subtype.
RESULTS: Our findings indicate that high Body Mass Index (BMI) was significantly associated with improved PFS (HR = 0.015; 95% CI, 0.001 to 0.477; p = 0.015), potentially attributed to increased infiltration of PD1 + T cells. A total of 91 differentially expressed FAMRGs were identified between the response and non-response groups in pan-cancer patients treated with immunotherapy. Of these, 6 hub FAMRGs (ACSL5, PLA2G2D, PROCA1, IL4I1, UBE2L6 and PSME1) were found to affect PD-1 expression and T cell infiltration in HNSCC, which may impact the efficacy of anti-PD1 therapy.
CONCLUSION: This study demonstrates that obesity serves as a robust prognostic predictor for patients with OTSCC undergoing neoadjuvant anti-PD1 therapy. Furthermore, the expression of 6 hub FAMRGs (ACSL5, PLA2G2D, PROCA1, IL4I1, UBE2L6 and PSME1) plays a pivotal role in the context of anti-PD1 therapy and deserves further investigation.
The invention relates to a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified in a characteristic manner after viral infection. The agent includes at least one component, selected from a group of materials, comprising histones, covalently-modified histones, polypeptides similar to histones and biologically-active sequences of the histones and peptides similar to histones. The agent may, for example, be recombinant human histone H1 or at least an H1 subtype (H1.0, H1.1, H1.2, HI.3, H1.4, H1.5, H1. t, H1.x) or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity. The invention further relates to a biochip for the diagnosis of virally-infected cells, whereby a selected number of differing biological agents, each having biological activity are arranged on the biochip, which serves to determine an individual profile for the disease, whereby the agents are selected from a group of materials comprising histones, covalently-modified histones, peptides similar to histones and biologically-active sequences of the histones and peptides similar to histones.